Human parvovirus B19 in young male patients with hemophilia A: Associations with treatment product exposure and joint range-of-motion limitation

Transfusion

Volumn 44, Issue 8, 2004, Pages 1179-1185

  Soucie, J Michael ^a   Siwak, Edward B ^b   Hooper, W Craig ^b   Evatt, Bruce L ^b   Hollinger, F Blaine ^b  

^a Hemophilia Surveillance   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B 19 IMMUNOGLOBULIN G; IMMUNOGLOBULIN G; PLASMA DERIVED FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; DRUG SAFETY; HEMOPHILIA A; HUMAN; HUMAN PARVOVIRUS B19; INFORMATION PROCESSING; JOINT LIMITATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARVOVIRUS; RISK FACTOR; SEROPREVALENCE; STATISTICAL ANALYSIS; UNITED STATES; VIRUS INACTIVATION; VIRUS TRANSMISSION;

AGE FACTORS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG CONTAMINATION; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; RANGE OF MOTION, ARTICULAR; RECOMBINANT PROTEINS;

EID: 3342895759     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.04029.x     Document Type: Article

References (22)

1. Brown KE, Young NS. Human parvovirus B19 infections in infants and children. Adv Pediatric Infectious Dis 1997;13:101-26.
2. White DG, Woolf AD, Mortimer PP, et al. Human parvovirus arthropathy. Lancet 1985;i:419-21.
3. Reid DM, Reid TMS, Brown T, Rennie JAN, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985;i:422-5.
4. Murai C, Munakata Y, Takahashi Y, et al. Rheumatoid arthritis after human parvovirus B19 infection. Ann Rheum Dis 1999;58:130-2.
5. Altschuler EL. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet 1999;354:1026-7.
6. Kishore J, Misra R, Gupta D, Ayyagari A. Raised IgM antibodies to parvovirus B19 in juvenile rheumatoid arthritis. Indian J Med Res 1998;107:15-8.
7. Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE. The prevalence of antibody to HPV in hemophiliacs and in the general population. Zbl Bakt 1996;284:232-40.
8. Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 1997;37:517-22.
9. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999;13:194-204.
10. Eis-Hubinger AM, Sasowski U, Brackmann HH, et al. Parvovirus B19 is frequently present in recombinant coagulation factor VIII products (letter). Thromb Haemost 1996;76:1120.
11. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools, implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996;93:714-9.
12. Lefrere JJ, Mariotti M, De La Croix I, et al. Albumin batches and B19 parvovirus DNA. Transfusion 1995;35:389-91.
13. Gaboulaud V, Parquet A, Tahiri C, et al. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F) VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol 2001;116:383-9.
14. Centers for Disease Control and Prevention. Blood safety monitoring among persons with bleeding disorders - United States May 1998-June 2002. MMWR Morb Mortal WkIy Rep 2003;51:1152-4.
15. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
16. American Academy of Orthopaedic Surgeons. Joint motion: method of measuring and recording. Chicago: American Academy of Orthopaedic Surgeons; 1965.
17. Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Transfusion 2002;118:1187-9.
18. Dijkmans BA, van Elsacker-Niele AM, Salimans MM, et al. Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum 1988;31:279-81.
19. Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992;12:147-51.
20. Soderlund M, von Essen R, Haapasaari J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063-5.
21. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004;103:2467-73.
22. Allain JP, Thomas I, Sauleda S. Nucleic acid testing for emerging viral infections. Transfus Med 2002;12:275-83.